ARCS Signature Program
Posted: 16 November 2022 Closes: 13 February 2023 The ARCS Signature Program is designed for senior executives and emerging leaders who are working in the med tech, biotech and pharmaceutical sectors. This includes those who are part of…
Backing business events to support jobs and innovation
Posted: 15 November The City of Melbourne has doubled its funding to support conferences, workshops and other business events – bringing more people together to drive innovation and boost the economy. An augmented reality festival, sustainable tech pitch…
Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC
Posted: 11 November Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced compelling new clinical data from the TACTI-002 all-comer PD-L1 Phase II trial evaluating Immutep’s lead product candidate, eftilagimod alpha…
Researchers make strides in the fight against COVID-19
Posted: 9 November New research from the Peter Doherty Institute of Infection and Immunity (Doherty Institute), The University of Melbourne and WEHI has unlocked key information in our understanding of molecular immune responses to COVID-19. Following COVID-19 infection,…
Virus discovery could help fight cancer
Posted: 9 November In a world first, La Trobe University researchers have discovered a virus that attacks a prominent disease-causing bacterium – a “ringleader” that recruits harmful bacteria to cause periodontitis, and potentially helps cancer grow and spread.…
Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Cutaneous T-Cell Lymphoma
Posted: 8 November The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced that they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the…
Monash and Hudson Institute teams’ world-first for newborns
Posted: 4 November Melbourne scientists have discovered a way to treat seizures in newborns that will not only help protect their developing brain from further injury, but may also provide the first new, safe and effective treatment in decades.…
Landmark study finds home screening test can help prevent type 1 diabetes
Posted: 4 November Researchers have shown that a blood test for early diagnosis of type 1 diabetes can prevent serious illness and hospitalisation in children. The innovative test is a finger prick sample that is collected at home and…
CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology
Posted: 4 November CSL Limited announced that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc to access their late stage self-amplifying mRNA (sa-mRNA) vaccine platform technology. Arcturus Therapeutics is…
VivaZome executives to present at Annual Exosome Scientific Conference
Posted: 4 November VivaZome Therapeutics Pty Ltd (VivaZome) has announced that Ms Xenia Sango, Head of Regulatory and Clinical is speaking at Australia and New Zealand Society for Extracellular Vesicles (ANZSEV) in Gold Coast, Queensland 9 – 11…
Health and the 2022-23 Federal Budget
Posted: 3 November Federal Treasurer Jim Chalmers recently delivered the 2022-2023 Budget. He announced new public health initiatives in Australia and increases in funding for foreign aid, regional and global health, climate change and the environment. Australian Global…
